Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 17/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.83 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12176983 | 0.91 | CYP17A1 (1.00) | CYP17A1CYP1A2 | |
| SCHEMBL2595437 | 0.88 | CYP17A1 (0.77) | CYP17A1CYP1A2 | |
| SCHEMBL14694482 | 0.86 | CYP17A1 (1.00) | CYP17A1CYP1A2 | |
| SCHEMBL12177210 | 0.86 | CYP17A1 (0.78) | CYP17A1CYP1A2 | |
| SCHEMBL14706954 | 0.86 | CYP17A1 (0.81) | CYP17A1CYP1A2 | |
| SCHEMBL14694478 | 0.85 | CYP17A1 (1.00) | CYP17A1CYP1A2 | |
| SCHEMBL14694387 | 0.84 | CYP17A1 (0.79) | CYP17A1CYP1A2IDO1 | |
| SCHEMBL14694394 | 0.84 | CYP17A1 (1.00) | CYP17A1CYP1A2IDO1DYRK3CCNA2 | |
| SCHEMBL2591189 | 0.84 | CYP17A1 (0.79) | CYP17A1CYP1A2 | |
| SCHEMBL2588731 | 0.84 | CYP17A1 (1.00) | CYP17A1CYP1A2IDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | claimed |
| EP-2563792-B1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | claimed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | claimed |
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2563792-B1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | CYP2C19, CYP3A7, CYP2C18 | CYP17A1 54/4885CYP1A2 9/4885IDO1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.